Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Bisphosphonates are nonbiodegradable pyrophosphate analogues that are being used increasingly to inhibit bone resorption in disorders characterized by excessive bone loss. We have previously found that dichloromethylene bisphosphonate (Cl2MBP) inhibits bone resorption through injury to the cells that resorb Cl2MBP-contaminated surfaces. 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (AHPrBP) is a more potent inhibitor of bone resorption in vivo, and we have attempted to identify a step in the resorptive pathway that accounts for this increased potency. We found that when osteoclasts, isolated from neonatal rat long bones, were incubated on bone slices in the presence of bisphosphonates, AHPrBP was less, rather than more potent as a resorption-inhibitor than Cl2MBP. The greater sensitivity of resorption to AHPrBP in vivo could neither be attributed to an effect of AHPrBP on the ability of osteoblastic cells to stimulate resorption in response to calcium-regulating hormones in vitro nor to an effect on osteoclast generation: osteoclast formation was unaffected by concentrations of AHPrBP 10-fold higher than those of Cl2MBP which inhibit bone resorption in the bone slice assay. We also found no evidence for impaired osteoclast generation in vivo in AHPrBP-treated rats. These results suggest that the comparisons of potency in vitro do not include all the factors responsible for determining bisphosphonate potency in vivo. Because bisphosphonates owe the specificity of their actio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This phenomenon is consistent with previous observations that bisphosphonates suppress bone resorption via injury to osteoclasts when they solubilize bisphosphonate-contaminated bone (139, 140).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [139]
Citations
Cites
Calcitonin alters behaviour of isolated osteoclasts
Chambers, T. J., & Magnus, C. J. (1982) · The Journal of Pathology · doi:10.1002/path.1711360104 · Cited by 504 · cited 1×
“Osteoclasts were isolated from neonatal rat long bones as previously described [28].”
MethodSelf-citationSchenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Osteoblastic Cells Mediate Osteoclastic Responsiveness to Parathyroid Hormone*
McSHEEHY, P. M. J., & CHAMBERS, T. J. (1986) · Endocrinology · doi:10.1210/endo-118-2-824 · Cited by 407 · cited 3×
“The number of resorption pits and the plan area of bone resorption were assessed as previously described [29].”
BackgroundMethodSelf-citationThe binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381 · cited 1×
“Bisphosphonates (PCPs) are nonbiodegradable analogues of pyrophosphate with a high binding affinity for hydroxyapatite crystals [1].”
BackgroundHughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357 · cited 2×
“Other experimental models that test the function of mature osteoclasts have similarly failed to demonstrate increased potency for AHPrBP, and this has led to the suggestion that AHPrBP impairs osteoclast generation [25].”
BackgroundTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Reid, I. R., Alexander, C. J., King, A. R., & Ibbertson, H. K. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92721-3 · Cited by 341
(1985) · De Gruyter eBooks · doi:10.1515/9783112330005 · Cited by 325
Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., & Blair, H. C. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114459 · Cited by 314 · cited 1×
“[38] who, using chick osteoclasts, found that AHPrBP was more potent than C12MBP by an order of magnitude.”
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306 · cited 2×
“The relative potency of 3-amino-l-hydroxypropyl idene- l , l -b isphosphonate (AHPrBP, formerly APD), as judged by inhibition of bone resorption in organ culture, does not correlate with the increased relative potency of AHPrBP in vivo [16].”
Background
Research works printed but not linked: 3
- Huaux JP, Devogelaer JP, Brasseu JP, Nagant de Deuxchaisnes C (1985) Effect of the diphosphonate APD on dual photon absorptiometry in involutional osteoporosis. In: Norman AW (ed) Vitamin D. A chemical, biochemical and clinical update. Walter de Gruyter, Berlin, pp 998–999
- Ende JJ (1978) Some effects of EHDP and Cl2MDP on the metabolism of isolated bone cells. Proc Kon Med Akad Wet C81:252–264
- Ende JJ, van Rooijen HJM (1979) Some effects of EHDP and Cl2MBP on enzyme activiyt and substrate utilisation by mouse calvaria in tissue culture. Proc Kon Med Akad Wet C. 82:55–63
Cited by
Items 101–173 of 173
Yamada, T., Muguruma, H., Yano, S., Ikuta, K., Ogino, H., Kakiuchi, S., Hanibuchi, M., Uehara, H., Nishioka, Y., & Sone, S. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0874 · Cited by 21
“PTHrP antibody 5 6 (5-7)c 24 (10-40) 82 (26-142)”
BackgroundMethodInfluentialÜlker, G. M. Y., Cumbul, A., Duygu, G., Uslu, Ü., & Sencift, K. (2017) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2017.04.017 · Cited by 21
Ma, N., Liu, L., Min, J., Wang, J.-W., Jiang, W., Liu, Y., Feng, Y.-G., Su, H., Ying-ming, F., & Zhang, H. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9408-6 · Cited by 17
Tamura, Y., Miyakoshi, N., Itoi, E., Abe, T., Kudo, T., Tsuchida, T., Kasukawa, Y., & Satô, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.3.541 · Cited by 18
Relationship between bisphosphonate concentration and osteoclast activity and viability
Rowe, D. J., Etre, L. A., Lovdahl, M. J., & Pietrzyk, D. J. (1999) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-999-0112-7 · Cited by 19
Nishikawa, M., Yamamoto, M., Murakami, T., Akatsu, T., Kugai, N., & Nagata, N. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.6.986 · Cited by 17
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.
SINIGAGLIA, L., VARENNA, M., & Casari, S. (2007) · PubMed · Cited by 17
The Molecular Mechanisms of Action of Bisphosphonates
Thompson, K., & Rogers, M. J. (2007) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-007-9004-0 · Cited by 14
Liu, H., Cui, J., Sun, J., Du, J., Feng, W., Sun, B., Li, J., Han, X., Liu, B., Yimin, et al. (2015) · Journal of Molecular Histology · doi:10.1007/s10735-015-9620-9 · Cited by 11
“Previous studies have reported that osteoclasts often detach from the bone surface after treatment with BPs (Flanagan and Chambers 1991; Jobke et al. 2014).”
BackgroundBisphosphonates: From Pharmacology to Treatment
Ruggiero, A., Triarico, S., Romano, A., Maurizi, P., Attinà, G., & Mastrangelo, S. (2023) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2603 · Cited by 15
The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates.
Goto, S., Noguchi, A., Jinguji, H., & Takahara, M. (2006) · PubMed · Cited by 11
Caffeic Acid Inhibits NFkappaB Activation of Osteoclastogenesis Signaling Pathway
Sandra, F., Kukita, T., Tang, Q. Y., & Iijima, T. (2011) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v3i3.153 · Cited by 11
Jarvis, M. F., Burns, C. J., Pauls, H. W., Assal, A. A., Kim, J. S., Cheney, D. L., & Youssefyeh, R. D. (1993) · Calcified Tissue International · doi:10.1007/bf00310202 · Cited by 11
Tobias, J. H., Laversuch, C. J., Chambers, T. J., & Gallagher, A. C. (1996) · Rheumatology · doi:10.1093/rheumatology/35.7.636 · Cited by 11
Self-citationAzria, M., Behhar, C., & Cooper, S. (1993) · Calcified Tissue International · doi:10.1007/bf00675621 · Cited by 11
Seifi, M., Asefi, S., Hatamifard, G., & Lotfi, A. (2017) · Europe PMC (PubMed Central) · doi:10.15171/joddd.2017.045 · Cited by 10
Short-term effects of zoledronate on the histomorphology of osteoclast in young albino rats
Ralte, S., Khatri, K., & Nagar, M. (2011) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2011.03.009 · Cited by 11
Hamano, T., Fujii, N., Nagasawa, Y., Isaka, Y., Moriyama, T., Okada, N., Imai, E., Horio, M., & Ito, T. (2006) · Bone · doi:10.1016/j.bone.2006.04.022 · Cited by 10
“5 [17–80] 34 [17–67] Vitamin D (±) 112/32 36/19 Urinary protein (−/±/+/++/+++) (44/25/13/10/5) (12/12/6/3/0) PSL dose (mg/day) 7.”
In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis, I., Kousidou, O. C., & Karamanos, N. K. (2005) · PubMed · Cited by 12
Nitzsche, Á., Hennig, C., von Brandenstein, K., Döding, A., Schulze‐Späte, U., Symmank, J., & Jacobs, C. (2024) · Cells · doi:10.3390/cells13020147 · Cited by 13
“This affects the bone metabolism with possible side effects such as antiresorptive-agent-related osteonecrosis of the jaw [31–34].”
BackgroundArkko, S., Zlatev, H., Mönkkönen, H., Räikkönen, J., Benzaïd, I., Clézardin, P., Mönkkönen, J., & Määttä, J. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.030 · Cited by 9
Volumes of chick and rat osteoclasts cultured on glass
Piper, K., BOYDE, A., & Jones, S. J. (1995) · Calcified Tissue International · doi:10.1007/bf00301607 · Cited by 9
Collagen Cross-Linking and Metabolism
Robins, S. P., & Brady, J. D. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50115-3 · Cited by 9
Kaur, K., Sun, Y., Kanayama, K., Morinaga, K., Hokugo, A., Nishimura, I., & Jewett, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111627 · Cited by 9
“Due to the strong affinity for bone minerals, BPs can preferentially target OCs in a variety of ways, including effects on OCs differentiation and their recruitment to the bone surface (21), inhibition of OCs adhesion (22), inhibition of OCs activity on the bone surface (23, 24), and shortening of OCs life span by pro…”
BackgroundMicheletti, C., DiCecco, L., Wexell, C. L., Binkley, D. M., Palmquist, A., Grandfield, K., & Shah, F. A. (2022) · JBMR Plus · doi:10.1002/jbm4.10693 · Cited by 8
“(12, 14) However, this surface appearance remains poorly understood and rather paradoxical because such irregular edges are usually indicative of ongoing osteoclast-mediated resorption, which should be largely suppressed by BPs.(3) Moreover, if the irregular edges were due to resorption only, this would not explain th…”
BackgroundInfluentialThe bisphosphonate incadronate for bone metastases of breast cancer
Koizumi, M., Kobayashi, M., Furukawa, M., Yamashita, T., & Ogata, E. (2000) · International Journal of Clinical Oncology · doi:10.1007/pl00012044 · Cited by 7
Emerging Role of Enzyme-Immobilized Nanocarriers in Osteoporosis: Advances and Challenges
Tang, N., Huang, Y., Zhu, Y., & Zhou, H. H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s557453 · Cited by 7
“74 One of the possible approaches to diminish the rate of bone resorption are based on blocking the Cathepsin K (CatK) – extracellular matrix proteases enzyme which has significant importance for the osteoclasts.”
Kurşun, B. Ü., & Akan, E. (2023) · Brazilian Oral Research · doi:10.1590/1807-3107bor-2023.vol37.0089 · Cited by 6
Gastrointestinal diseases of athletic horses
Nieto, J. E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4771-8.00047-8 · Cited by 6
Kitsugi, T., Yamamuro, T., Nakamura, T., & Oka, M. (1995) · The Journal of Arthroplasty · doi:10.1016/s0883-5403(05)80134-2 · Cited by 6
Brief Review: Virtual Reality and Physical Exercise as Countermeasures of Coping the Space Missions
Russomano, T., Vinagre, N. A. C., Gessinger, R. P., Castro, J. D. C., Herbert, J. D. S., de Oliveira, A. A., Oliveira, E., Costa, K. L. G., Xavier, A. P., Ruiz, R., et al. (2024) · Health Nexus · doi:10.61838/kman.hn.2.2.4 · Cited by 5
Sugiura, Y., Ono, F., Nohara, M., Funabiki, M., Kutara, K., Kanda, T., Yamada, E., & Horie, M. (2024) · Regenerative Therapy · doi:10.1016/j.reth.2024.08.021 · Cited by 5
Consolaro, A. G., & Consolaro, M. F. M.-O. (2008) · Revista Dental Press de Ortodontia e Ortopedia Facial · doi:10.1590/s1415-54192008000400003 · Cited by 5
Puetate, J. C. S., Silva, B. L. G., Pinotti, F. E., Marcantonio, C. C., de Oliveira, G. J. P. L., Marcantônio, É., & Marcantonio, R. A. C. (2024) · Clinical Oral Investigations · doi:10.1007/s00784-023-05480-7 · Cited by 7
“…regulators of bone mineralization that can inhibit bone resorption by osteoclastic cells through four mechanisms: induction of apoptosis [6, 7], inhibition of recruitment to the bone surface [8], inhibition of adhesion of these cells [9], and osteoclastic activity on the bone surface [10, 11].”
Pazzaglia, U. E., Andrini, L., Leutner, M., & Nucci, A. D. (1998) · Orthopedics · doi:10.3928/0147-7447-19980201-14 · Cited by 5
Bilsky, M. H., & Vitaz, T. W. (2005) · Elsevier eBooks · doi:10.1016/b978-0-443-06616-0.50081-x · Cited by 5
Kouloulias, V., Dardoufas, C., Kouvaris, J., Gennatas, C., & Vlahos, L. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.2106 · Cited by 5
Adhesive and Bone Resorptive Activities of Isolated Osteoclasts from Hen Medullary Bone.
Sugiyama, T., & KUSUHARA, S. (1998) · Journal of Veterinary Medical Science · doi:10.1292/jvms.60.573 · Cited by 4
Mechanisms of Action of Bisphosphonates as Inhibitors of Bone Resorption
Rogers, M. J., & Russell, R. G. G. (1996) · Medical intelligence unit · doi:10.1007/978-3-662-22505-9_7 · Cited by 5
Kouloulias, V., Kouvaris, J., Mystakidou, K., Varela, M. N., Kokakis, J. D., Pistevou-Gombaki, K., Balafouta, M., Gennatas, C., & Vlahos, L. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003331 · Cited by 3
In Vitro Regulation of Osteoblast Activity
Karin, N. J., & Farach‐Carson, M. C. (2004) · Springer eBooks · doi:10.1007/978-1-4471-3777-1_2 · Cited by 3
Hyperparathyroidism secondary to zoledronic acid infusion: case report
Sayın, M., & Yazıcı, G. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0591-9 · Cited by 3
“They are potent inhibitors of osteoclast-mediated bone resorption, and are shown to be effective in reducing skeletal complications such as bone pain, pathologic fracture, bone surgery, and hypercalcemia [1–5].”
BackgroundTotal Hip Arthroplasty: Osteolysis and its Prevention with Systemic Therapy
Lyons, A. R. (1998) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.1998.11930074 · Cited by 3
Ortiz, M. A., Anguera, G., Cantó, E., Alejandre, J., Móra, J., Osuna‐Gómez, R., Mulet, M., Mora, P., Antonijuan-Parés, A., Sánchez, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104669 · Cited by 3
“Additionally, bisphosphonates that inhibit bone resorption decreased NTx/Cr levels in urine [27,28].”
Effect of Bisphosphonate on Osteoclast of Bone
Ralte, S., & Bhattacharyya, A. (2014) · Forensic Medicine and Anatomy Research · doi:10.4236/fmar.2014.23011 · Cited by 2
“• Interference with chemotaxis and attachment of osteoclast to bone [26].”
BackgroundEvaluation of a protocol for studying the chick chorioallantoic membrane in vitro
Packard, M. J. (1999) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/s1095-6433(99)00121-x · Cited by 2
Suppression of cementum-like tissue formation on BMP-2-applied dentin surface by bisphosphonate
Hongo, T., Miyaji, H., Sugaya, T., & Kawanami, M. (2006) · 日本歯周病学会会誌 · doi:10.2329/perio.48.285 · Cited by 2
Oral continuous clodronate in the prevention of early postmenopausal bone loss
Paparella, P., Giorgino, R., & Mancuso, S. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85038-4 · Cited by 2
Santamaria, M. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.25.2009.tde-30062009-163844 · Cited by 2
Henning, P., Westerlund, A., Movérare‐Skrtic, S., Lindholm, C., Márquez, M., Nilsson, S. F., Holmberg, A., & Lerner, U. H. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01427-1 · Cited by 1
“BPs bound to bone become internalized in osteoclasts [14] when these cells resorb bone, which causes accumulation of BPs at concentrations high enough to inhibit osteoclast activity through apoptotic cell death [15, 16].”
BackgroundThe Role of Bisphosphonates in Childhood Diseases
Attinà, G., Mastrangelo, S., & Ruggiero, A. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2251 · Cited by 1
Revisión de las implicaciones clínicas del ácido zoledrónico en el tratamiento del dolor
Vidal, M. A., Benítez, D., & Torres, L. M. (2006) · Dialnet (Universidad de la Rioja) · Cited by 1
Vasconcelos, E. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.25.2013.tde-04062013-095900 · Cited by 1
Kowolik, M. J., & Hyvönen, P. M. (1994) · Inflammopharmacology · doi:10.1007/bf02678603 · Cited by 1
Effects of Hormone Deprivation in Survivors of Breast and Prostate Cancer
Hershman, D. L., Ritchie, E. K., & Rosner, Z. (2004) · Principles of Gender-Specific Medicine · doi:10.1016/b978-012440905-7/50328-5
Adams, C. S., & Horton, W. E. (2001) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(01)06010-2
Clézardin, P., Gligorov, J., & Delmas, P. D. (2000) · Revue du Rhumatisme · doi:10.1016/s1169-8330(00)80044-7
A New Schedule for Clodronate Treatment in Patients with Breast Cancer and Bone Metastases
BEGHÉ, F., & Luzzani, M. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb17228.x
Bisphosphonate effects upon relapse of orthodontically moved teeth
Osman, H., & Afify, A. K. (2006) · Egyptian Orthodontic Journal · doi:10.21608/eos.2006.79223
Liposomal Bisphosphonates for the Treatment of Restenosis
Epstein-Barash, H., Afergan, E., Koroukhov, N., Eisenberg, G., Gutman, D., & Golomb, G. (2016) · CRC Press eBooks · doi:10.1201/9780849397271-14
Osteoclast Recruitment in Mice is Stimulated by (3-Amino-l-Hydroxypropylidene)-l,l-Bisphosphonate
Marshall, M. J. E., Holt, I., William, M., Davie, J. R., Jones, R. H., & Hunt, A. (1993)
Role of Osteoclasts in potential pathogenic mechnism of ONJ
Kaur, K. (2015) · eScholarship (California Digital Library)
Català, E., & Martinez, M. J. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0261-5.50030-2
A humanized model to investigate targeted therapeutic strategies against cancer bone metastasis
Landgraf, M. (2020) · Queensland University of Technology · doi:10.5204/thesis.eprints.204176
Dillstrom, D. (2018) · Deep Blue (University of Michigan)
Staging, Classification, and Oncologic Approaches for Metastatic Tumors Involving the Spine
Elder, J. B., Laufer, I., Vitaz, T. W., & Bilsky, M. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-40030-5.00114-3
Liposomal Bisphosphonates for the Treatment of Restenosis
Epstein-Barash, H., Afergan, E., Koroukhov, N., Eisenberg, G., Gutman, D., & Golomb, G. (2006) · Informa Healthcare eBooks · doi:10.1201/9780849397271.ch10
Muguruma, H., Yano, S., Kakiuchi, S., Uehara, H., Kawatani, M., Osada, H., & Sone, S. (2023) · doi:10.1158/1078-0432.c.6518077.v1
Muguruma, H., Yano, S., Kakiuchi, S., Uehara, H., Kawatani, M., Osada, H., & Sone, S. (2023) · doi:10.1158/1078-0432.c.6518077
Kaur, K., & Jewett, A. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023051091
Localized Osteolysis after Joint Replacement Surgery
Shanbhag, A. S., & Rubash, H. E. (2000) · Springer eBooks · doi:10.1007/978-1-4471-3825-9_40
Metadata
- Authors
- Flanagan, A. M., & Chambers, T. J.
- Affiliations
- St George's Hospital (GB)
- St George's, University of London (GB)
- Venue
- Calcified Tissue International
- Published
- 1991-11
- Volume
- 49
- Issue
- 6
- Pages
- 407-415
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2004135633
- Cited by
- 171
- References
- 39
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 6 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, pyrophosphate analogues, calcitonin, osteoblasts
- MeSH terms
- Pamidronate, Animals, Bone and Bones, Bone Marrow Cells, Bone Resorption, Calcitonin, Cells, Cultured, Clodronic Acid, Diphosphonates, Microscopy, Electron, Osteoclasts, Rats, Inbred Strains, Culture Techniques, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.